Forensic Dermatology Expert Analytical Report: A New Frontier of Forensic Medicine.

Specialists in forensic medicine assist in crime scene investigations. The forensic medicine experts include anthropologists, ballistic analysts, entomologists, odontologists, and osteologists. The experts are usually not at the crime scene; they provide an evaluation of evidence that is sent to them.

Expansion of an Academic Molecular Tumor Board to Enhance Access to Biomarker-Driven Trials and Therapies in the Rural Southeastern United States.

Targeting tumor-specific molecular alterations has shown significant clinical benefit. Molecular tumor boards (MTBs) connect cancer patients with personalized treatments and clinical trials. However, rural cancer centers often have limited access to MTB expertise.

Guided Imagery and Other Complementary Pain Control Approaches for Critical Care Patients.

For centuries, pharmacologic interventions have been the primary intervention for pain in intensive care patients. Opioid use has significant side effects and long-term risks including addiction and loss of life. Critical care nurses and other health care professionals can include effective nonpharmacological complementary modalities to reduce pain.

Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study.

Background: Despite advances in cancer care and detection, >65% of patients with squamous cell cancer of the head and neck (HNSCC) will develop recurrent and/or metastatic disease. The prognosis for these patients is poor with a 5-year overall survival of 39%. Recent treatment advances in immunotherapy, including immune checkpoint inhibitors like pembrolizumab and nivolumab, have resulted in clinical benefit in a subset of patients.

Association of Race and Ethnicity with Genomic Testing at a Comprehensive Cancer Center in North Carolina.

Non-Hispanic Black patients diagnosed with prostate cancer between 2014 and 2019 and treated at a comprehensive cancer center were less likely to use tumor-specific genomic testing compared with non-Hispanic White patients. Disparities in the use of precision oncology technologies should be monitored and addressed to ensure equitable cancer care.